Charles River Laboratories International, Inc. (CRL) and Akron Bio have announced the integration of Akron's Closed System Solutions (CSS) line of liquid cytokines, produced under current good manufacturing practices (CGMP), into Charles River's Cell Therapy Flex Platform for Process Development.
This integration enhances the closed system processing capabilities, thereby streamlining operations, minimizing risk, and improving process robustness. Charles River's Cell Therapy Flex Platform, an off-the-shelf solution for Cell Therapy Process Development, provides ready-to-use platforms and validated protocols for autologous CAR-T and TCR-T cell therapies. This design aims to mitigate risk, reduce costs, and expedite development timelines.
The platform now incorporates Akron's CGMP liquid cytokines, such as rHu IL-2, IL-7, IL-15, and IL-21, available in proprietary liquid formulations that ensure protein stability at 2-8°C.
These materials are offered in single-use bags with weldable tubing to minimize operator errors and facilitate rapid, seamless aseptic media formulation.
